Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2025)

C4 Therapeutics' EBITDA Margin history spans 7 years, with the latest figure at 186.78% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 48880.0% year-over-year to 186.78%; the TTM value through Dec 2025 reached 292.24%, up 322.0%, while the annual FY2025 figure was 292.09%, 337.0% up from the prior year.
  • EBITDA Margin reached 186.78% in Q4 2025 per CCCC's latest filing, up from 285.39% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 81.07% in Q4 2021 to a low of 1322.3% in Q2 2023.
  • Average EBITDA Margin over 5 years is 496.37%, with a median of 327.6% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -117727bps in 2022, then soared 117424bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 81.07% in 2021, then tumbled by -1452bps to 1258.34% in 2022, then increased by 17bps to 1041.92% in 2023, then skyrocketed by 35bps to 675.58% in 2024, then soared by 72bps to 186.78% in 2025.
  • Per Business Quant, the three most recent readings for CCCC's EBITDA Margin are 186.78% (Q4 2025), 285.39% (Q3 2025), and 403.73% (Q2 2025).